Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_1
1
17%
Ph early_phase_1
1
17%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(3)
Other(1)

Detailed Status

Withdrawn2
Completed2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (20.0%)
Phase 11 (20.0%)
Phase 23 (60.0%)

Trials by Status

unknown117%
withdrawn233%
terminated117%
completed233%

Recent Activity

0 active trials
Showing 5 of 6
withdrawnearly_phase_1

Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer

NCT03473691
completedphase_2

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02487979
completedphase_2

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

NCT02363283
terminatedphase_2

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

NCT02302339
withdrawnphase_1

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

NCT03326258
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03473691Early Phase 1

Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer

Withdrawn
NCT02487979Phase 2

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

Completed
NCT02363283Phase 2

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

Completed
NCT02302339Phase 2

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Terminated
NCT03326258Phase 1

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Withdrawn
NCT03067935

Individual Patient Expanded Access-Glembatumumab Vedotin

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6